The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
The origin of NMDA receptor hypofunction in schizophrenia
Open accessAbstract
N-methyl-d-aspartate (NMDA) receptor (NMDAR) hypofunction plays a key role in pathophysiology of schizophrenia. Since NMDAR hypofunction has also been reported in autism, Alzheimer’s disease and cognitive dementia, it is crucial to identify the location, timing, and mechanism of NMDAR hypofunction for schizophrenia for better understanding of disease etiology and for novel therapeutic intervention. In this review, we first discuss the shared underlying mechanisms of NMDAR hypofunction in NMDAR antagonist models and the anti-NMDAR autoantibody model of schizophrenia and suggest that NMDAR hypofunction could occur in GABAergic neurons in both models. Preclinical models using transgenic mice have shown that NMDAR hypofunction in cortical GABAergic neurons, in particular parvalbumin-positive fast-spiking interneurons, in the early postnatal period confers schizophrenia-related phenotypes. Recent studies suggest that NMDAR hypofunction can also occur in PV-positive GABAergic neurons with alterations of NMDAR–associated proteins, such as neuregulin/ErbB4, α7nAChR, and serine racemase. Furthermore, several environmental factors, such as oxidative stress, kynurenic acid and hypoxia, may also potentially elicit NMDAR hypofunction in GABAergic neurons in early postnatal period. Altogether, the studies discussed here support a central role for GABAergic abnormalities in the context of NMDAR hypofunction. We conclude by suggesting potential therapeutic strategies to improve the function of fast-spiking neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hollmann, M., & Heinemann, S. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.000335 · Cited by 3,975
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“…the observation that a sub-class of non-competitive NMDAR antagonists, phencyclidine (PCP) and ketamine, induces behaviors reminiscent of all three (positive, negative, and cognitive) symptoms of schizophrenia in human subjects (Coyle et al., 2003; Javitt and Zukin, 1991; Krystal et al., 1994).”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Synaptic Plasticity and Memory: An Evaluation of the Hypothesis
Martin, S. J., Grimwood, P. D., & Morris, R. G. M. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.649 · Cited by 2,794 · cited 1×
“In mature cortical principal neurons, NMDARs mediate glutamatergic excitatory neurotransmission and play an important role in learning and memory through induction of synaptic plasticity (Martin et al., 2000; Nakazawa et al., 2004).”
BackgroundThe Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693 · cited 3×
“dopamine release as a final common pathway to evoke positive symptoms (Howes and Kapur, 2009).”
BackgroundInfluentialClinical experience and laboratory investigations in patients with anti-NMDAR encephalitis
Dalmau, J., Lancaster, E., Martinez-Hernandez, E., Rosenfeld, M. R., & Balice-Gordon, R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70253-2 · Cited by 2,435
Semple, B. D., Blomgren, K., Gimlin, K., Ferriero, D. M., & Noble-Haeusslein, L. J. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.04.001 · Cited by 2,132
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“If their binding to the open-state of NMDARs is the origin of psychotic symptoms, it is tempting to speculate that NMDAR hypofunction takes places in cortical and hippocampal GABAergic neurons in idiopathic schizophrenia (Cohen et al., 2015; Coyle, 2006; Inan et al., 2013; Ju and Cui, 2016; Lisman et al., 2008; Moreau…”
BackgroundGoldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Three-dimensional intact-tissue sequencing of single-cell transcriptional states
Wang, X., Allen, W. E., Wright, M. A., Sylwestrak, E. L., Samusik, N., Vesuna, S., Evans, K., Liu, C., Ramakrishnan, C., Liu, J., et al. (2018) · Science · doi:10.1126/science.aat5691 · Cited by 1,620
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530 · cited 1×
“KYNA is a metabolite in the neuroprotective branch of the kynurenine pathway of tryptophan degradation (Erhardt et al., 2017; Schwarcz et al., 2012).”
BackgroundA Systematic Survey of Loss-of-Function Variants in Human Protein-Coding Genes
MacArthur, D. G., Balasubramanian, S., Frankish, A., Huang, N., Morris, J., Walter, K., Jostins, L., Habegger, L., Pickrell, J. K., Montgomery, S. B., et al. (2012) · Science · doi:10.1126/science.1215040 · Cited by 1,272
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis
Hughes, E. G., Peng, X., Gleichman, A. J., Lai, M., Zhou, L., Tsou, R., Parsons, T. D., Lynch, D. R., Dalmau, J., & Balice-Gordon, R. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0167-10.2010 · Cited by 1,143
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010 · cited 1×
“If their binding to the open-state of NMDARs is the origin of psychotic symptoms, it is tempting to speculate that NMDAR hypofunction takes places in cortical and hippocampal GABAergic neurons in idiopathic schizophrenia (Cohen et al., 2015; Coyle, 2006; Inan et al., 2013; Ju and Cui, 2016; Lisman et al., 2008; Moreau…”
BackgroundGlutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917 · cited 2×
“…to speculate that NMDAR hypofunction takes places in cortical and hippocampal GABAergic neurons in idiopathic schizophrenia (Cohen et al., 2015; Coyle, 2006; Inan et al., 2013; Ju and Cui, 2016; Lisman et al., 2008; Moreau and Kullmann, 2013; Nakazawa et al., 2017; Nakazawa et al., 2012; Olney…”
BackgroundPostnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes
Belforte, J. E., Zsiros, V., Sklar, E. R., Jiang, Z., Yu, G., Li, Y., Quinlan, E. M., & Nakazawa, K. (2010) · Nature Neuroscience · doi:10.1038/nn.2447 · Cited by 752
Self-citationHuettner, J. E., & Bean, B. P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1307 · Cited by 751 · cited 1×
“This binding requires agonist-induced channel opening and sufficient cellular membrane depolarization to expel the Mg2+ ion from the channel pore (Halliwell et al., 1989; Huettner and Bean, 1988).”
BackgroundAutistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function
Won, H., Lee, H.-R., Gee, H. Y., Mah, W., Kim, J.-I., Lee, J., Ha, S., Chung, C., Jung, E. S., Cho, Y. S., et al. (2012) · Nature · doi:10.1038/nature11208 · Cited by 695 · cited 1×
“Whereas NMDAR overstimulation causes excitotoxicity and subsequent neurodegeneration, such as in stroke, head trauma, neuropathic pain, Huntington’s and Alzheimer’s disease (Zhou and Sheng, 2013), NMDAR hypofunction is also found in autism (Won et al., 2012), early-phase AD (Liu et al.”
BackgroundRoss, C. A., Margolis, R. L., Reading, S. A. J., Pletnikov, M., & Coyle, J. T. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.015 · Cited by 686
Carlén, M., Meletis, K., Siegle, J. H., Cardin, J. A., Futai, K., Vierling-Claassen, D., Rühlmann, C., Jones, S. R., Deisseroth, K., Sheng, M., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.31 · Cited by 669
The environment and susceptibility to schizophrenia
Brown, A. S. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.003 · Cited by 664
NMDA receptors, place cells and hippocampal spatial memory
Nakazawa, K., McHugh, T. J., Wilson, M. A., & Tonegawa, S. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1385 · Cited by 619 · cited 1×
“In mature cortical principal neurons, NMDARs mediate glutamatergic excitatory neurotransmission and play an important role in learning and memory through induction of synaptic plasticity (Martin et al., 2000; Nakazawa et al., 2004).”
BackgroundSelf-citationNeuregulin-ERBB Signaling in the Nervous System and Neuropsychiatric Diseases
Mei, L., & Nave, K.-A. (2014) · Neuron · doi:10.1016/j.neuron.2014.06.007 · Cited by 592
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585
Benros, M. E., Nielsen, P. R., Nordentoft, M., Eaton, W. W., Dalton, S. O., & Mortensen, P. B. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11030516 · Cited by 582
Structure, function, and allosteric modulation of NMDA receptors
Hansen, K. B., Yi, F., Perszyk, R. E., Furukawa, H., Wollmuth, L. P., Gibb, A. J., & Traynelis, S. F. (2018) · Journal of General Physiology · doi:10.1085/jgp.201812032 · Cited by 573
Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia
Hahn, C.-G., Wang, H.-Y., Cho, D.-S., Talbot, K., Gur, R. E., Berrettini, W. H., Bakshi, K., Kamins, J., Borgmann-Winter, K. E., Siegel, S. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1418 · Cited by 563
The Role of NMDA Receptors in Alzheimer’s Disease
Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00043 · Cited by 535
Antibodies to Toxoplasma gondii in Patients With Schizophrenia: A Meta-Analysis
Torrey, E. F., Bartko, J. J., Lun, Z.-R., & Yolken, R. H. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl050 · Cited by 503
Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling
Fazzari, P., Paternain, A. V., Valiente, M., Pla, R., Luján, R., Lloyd, K., Lerma, J., Marín, O., & Rico, B. (2010) · Nature · doi:10.1038/nature08928 · Cited by 501
Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses
Papadia, S., Soriano, F. X., Léveillé, F., Martel, M.-A., Dakin, K. A., Hansen, H. H., Kaindl, A., Sifringer, M., Fowler, J., Stefovska, V., et al. (2008) · Nature Neuroscience · doi:10.1038/nn2071 · Cited by 498
GABAergic interneuron origin of schizophrenia pathophysiology
Nakazawa, K., Zsiros, V., Jiang, Z., Nakao, K., Kolata, S., Zhang, S., & Belforte, J. E. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.022 · Cited by 498 · cited 1×
“If their binding to the open-state of NMDARs is the origin of psychotic symptoms, it is tempting to speculate that NMDAR hypofunction takes places in cortical and hippocampal GABAergic neurons in idiopathic schizophrenia (Cohen et al., 2015; Coyle, 2006; Inan et al., 2013; Ju and Cui, 2016; Lisman et al., 2008; Moreau…”
BackgroundSelf-citationTingley, W. G., Ehlers, M. D., Kameyama, K., Doherty, C., Ptak, J. B., Riley, C. T., & Huganir, R. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.8.5157 · Cited by 495
Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., Nakazato, M., Kumakiri, C., Okada, S.-I., Hasegawa, H., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.572 · Cited by 490
Korotkova, T., Fuchs, E. C., Ponomarenko, A., von Engelhardt, J., & Monyer, H. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.017 · Cited by 480 · cited 2×
“Nonetheless, the studies using PV-GRIN1 KO mice also reported impairment in gamma oscillations (Carlen et al., 2012; Korotkova et al., 2010).”
BackgroundThe chemical biology of clinically tolerated NMDA receptor antagonists
Chen, H. V., & Lipton, S. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03991.x · Cited by 474
The role of inflammation in schizophrenia
Müller, N., Weidinger, E., Leitner, B., & Schwarz, M. J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00372 · Cited by 465
Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology
Harrison, P. J., & Law, A. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.002 · Cited by 463
Selective modulation of NMDA responses by reduction and oxidation
Aizenman, E., Lipton, S. A., & Loring, R. H. (1989) · Neuron · doi:10.1016/0896-6273(89)90310-3 · Cited by 457
Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia
Genovese, G., Fromer, M., Stahl, E. A., Ruderfer, D. M., Chambert, K., Landén, M., Moran, J. L., Purcell, S. M., Sklar, P., Sullivan, P. F., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4402 · Cited by 444 · cited 1×
“Since a majority of GRIN rare variants found in mental disorders are loss-of-function mutations (Genovese et al., 2016; Kataoka et al., 2016; MacArthur et al., 2012), these mutations may elicit, or exacerbate the risk of, NMDAR hypofunction in some cell-types, depending on the mutation types.”
BackgroundConverging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia
COYLE, J. T., TSAI, G., & GOFF, D. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.020 · Cited by 442
Tricklebank, M. D., Singh, L., Oles, R. J., Preston, C., & Iversen, S. D. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90754-1 · Cited by 433
Woo, T.-U. W., Walsh, J. P., & Benes, F. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.649 · Cited by 411
Law, A. J., Lipska, B. K., Weickert, C. S., Hyde, T. M., Straub, R. E., Hashimoto, R., Harrison, P. J., Kleinman, J. E., & Weinberger, D. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602002103 · Cited by 402
Slifstein, M., van de Giessen, E., Van Snellenberg, J., Thompson, J. L., Narendran, R., Gil, R., Hackett, E., Girgis, R., Ojeil, N., Moore, H., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2414 · Cited by 398
Jentsch, J. D., Redmond, D. E., Elsworth, J. D., Taylor, J. R., Youngren, K. D., & Roth, R. H. (1997) · Science · doi:10.1126/science.277.5328.953 · Cited by 398
Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 396
Wang, A. K., & Miller, B. J. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx035 · Cited by 389
Redox dysregulation, neurodevelopment, and schizophrenia
Do, K. Q., Cabungcal, J. H., Frank, A., Steullet, P., & Cuenod, M. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.05.001 · Cited by 384
Xia, P., Chen, H.-S. V., Zhang, D., & Lipton, S. A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2488-10.2010 · Cited by 379
Kegeles, L. S., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J. J., Van Heertum, R. L., Cooper, T. B., Carlsson, A., & Laruelle, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00976-8 · Cited by 377
Cysteine regulation of protein function – as exemplified by NMDA-receptor modulation
Lipton, S. A., Choi, Y.-B., Takahashi, H., Zhang, D., Li, W., Godzik, A., & Bankston, L. A. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02245-2 · Cited by 375
Acute mechanisms underlying antibody effects in anti–N‐methyl‐D‐aspartate receptor encephalitis
Moscato, E. H., Peng, X., Jain, A., Parsons, T. D., Dalmau, J., & Balice‐Gordon, R. J. (2014) · Annals of Neurology · doi:10.1002/ana.24195 · Cited by 367
Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis
Mikasova, L., De Rossi, P., Bouchet, D., Georges, F., Rogemond, V., Didelot, A., Meissirel, C., Honnorat, J., & Groc, L. (2012) · Brain · doi:10.1093/brain/aws092 · Cited by 341
Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior
Basu, A. C., Tsai, G. E., Ma, C.-L., Ehmsen, J. T., Mustafa, A. K., Han, L., Jiang, Z. I., Benneyworth, M. A., Froimowitz, M. P., Lange, N., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.130 · Cited by 338
A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia
BENDIKOV, I., NADRI, C., AMAR, S., PANIZZUTTI, R., DEMIRANDA, J., WOLOSKER, H., & AGAM, G. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.10.010 · Cited by 323
Structure, Function, and Pharmacology of NMDA Receptor Channels
VYKLICKY, V., KORINEK, M., SMEJKALOVA, T., BALIK, A., KRAUSOVA, B., KANIAKOVA, M., LICHNEROVA, K., CERNY, J., KRUSEK, J., DITTERT, I., et al. (2014) · Physiological Research · doi:10.33549/physiolres.932678 · Cited by 321
Disease-relevant autoantibodies in first episode schizophrenia
Zandi, M. S., Irani, S. R., Lang, B., Waters, P., Jones, P. B., McKenna, P., Coles, A. J., Vincent, A., & Lennox, B. R. (2011) · Journal of Neurology · doi:10.1007/s00415-010-5788-9 · Cited by 319
Koek, W., Woods, J. H., & Winger, G. D. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24082-4 · Cited by 305
Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis
Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304
NMDA receptors in nervous system diseases
Zhou, Q., & Sheng, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.030 · Cited by 298
Pathway-Specific Dopamine Abnormalities in Schizophrenia
Weinstein, J. J., Chohan, M. O., Slifstein, M., Kegeles, L. S., Moore, H., & Abi-Dargham, A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.03.2104 · Cited by 297
Kann, O., Papageorgiou, I. E., & Draguhn, A. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.104 · Cited by 295
The 40-Hz Auditory Steady-State Response in Patients With Schizophrenia: A Meta-analysis
Thuné, H., Recasens, M., & Uhlhaas, P. J. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2619 · Cited by 292
Gleichman, A. J., Spruce, L. A., Dalmau, J., Seeholzer, S. H., & Lynch, D. R. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0064-12.2012 · Cited by 290
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Hu, W., MacDonald, M. L., Elswick, D. E., & Sweet, R. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12547 · Cited by 286
Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia
Hashimoto, R., Straub, R. E., Weickert, C. S., Hyde, T. M., Kleinman, J. E., & Weinberger, D. R. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001434 · Cited by 283
Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis
Fraguas, D., Díaz-Caneja, C. M., Ayora, M., Hernández-Álvarez, F., Rodríguez-Quiroga, A., Recio, S., Leza, J. C., & Arango, C. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby125 · Cited by 270
The kynurenine pathway in schizophrenia and bipolar disorder
Erhardt, S., Schwieler, L., Imbeault, S., & Engberg, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.020 · Cited by 255
Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis
Plitman, E., Iwata, Y., Caravaggio, F., Nakajima, S., Chung, J. K., Gerretsen, P., Kim, J., Takeuchi, H., Chakravarty, M. M., Remington, G., et al. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw221 · Cited by 251
Trapping Channel Block of NMDA-Activated Responses By Amantadine and Memantine
Blanpied, T. A., Boeckman, F. A., Aizenman, E., & Johnson, J. W. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.77.1.309 · Cited by 249
Kokkinou, M., Ashok, A. H., & Howes, O. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.190 · Cited by 247
Al-Diwani, A., Handel, A., Townsend, L., Pollak, T., Leite, M. I., Harrison, P. J., Lennox, B. R., Okai, D., Manohar, S. G., & Irani, S. R. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30001-x · Cited by 241
Human GRIN2B variants in neurodevelopmental disorders
Hu, C., Chen, W., Myers, S. J., Yuan, H., & Traynelis, S. F. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.10.002 · Cited by 236
Orlovska-Waast, S., Köhler-Forsberg, O., Brix, S. W., Nordentoft, M., Kondziella, D., Krogh, J., & Benros, M. E. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0220-4 · Cited by 233
Cohen, S. M., Tsien, R. W., Goff, D. C., & Halassa, M. M. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.026 · Cited by 232
Cai, H. Q., Catts, V. S., Webster, M. J., Galletly, C., Liu, D., O’Donnell, M., Weickert, T. W., & Weickert, C. S. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0235-x · Cited by 227
Schwieler, L., Larsson, M. K., Skogh, E., Kegel, M. E., Orhan, F., Abdelmoaty, S., Finn, A., Bhat, M., Samuelsson, M., Lundberg, K., et al. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140126 · Cited by 226
Elevations of Endogenous Kynurenic Acid Produce Spatial Working Memory Deficits
Chess, A. C., Simoni, M. K., Alling, T. E., & Bucci, D. J. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl033 · Cited by 225
Kornhuber, J., & Weller, M. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00047-9 · Cited by 222
Selective Expression of ErbB4 in Interneurons, But Not Pyramidal Cells, of the Rodent Hippocampus
Vullhorst, D., Neddens, J., Karavanova, I., Tricoire, L., Petralia, R. S., McBain, C. J., & Buonanno, A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2454-09.2009 · Cited by 220
GRIN2A -related disorders: genotype and functional consequence predict phenotype
Strehlow, V., Heyne, H. O., Vlaskamp, D. R. M., Marwick, K. F. M., Rudolf, G., de Bellescize, J., Biskup, S., Brilstra, E. H., Brouwer, O. F., Callenbach, P. M. C., et al. (2019) · Brain · doi:10.1093/brain/awy304 · Cited by 220
Halliwell, R. F., Peters, J. A., & Lambert, J. J. (1989) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1989.tb11841.x · Cited by 215
Oxygen free radicals regulate NMDA receptor function via a redox modulatory site
Aizenman, E., Hartnett, K. A., & Reynoldst, I. J. (1990) · Neuron · doi:10.1016/0896-6273(90)90343-e · Cited by 201
Encephalitis with mGluR5 antibodies: Symptoms and antibody effects
Spatola, M., Sabater, L., Planagumà, J., Martínez-Hernandez, E., Armangué, T., Prüss, H., Iizuka, T., Caparó Oblitas, R. L., Antoine, J.-C., Li, R., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005614 · Cited by 201
Delineating the GRIN1 phenotypic spectrum: A distinct genetic NMDA receptor encephalopathy
Lemke, J. R., Geider, K., Helbig, K. L., Heyne, H. O., Schütz, H., Hentschel, J., Courage, C., Depienne, C., Nava, C., Heron, D., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002740 · Cited by 200
Pollak, T. A., McCormack, R., Peakman, M., Nicholson, T. R., & David, A. S. (2013) · Psychological Medicine · doi:10.1017/s003329171300295x · Cited by 189
Herpes simplex virus–1 encephalitis can trigger anti-NMDA receptor encephalitis: Case report
Leypoldt, F., Titulaer, M. J., Aguilar, E., Walther, J., Bönstrup, M., Havemeister, S., Teegen, B., Lütgehetmann, M., Rosenkranz, M., Magnus, T., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a9f531 · Cited by 187
Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model
Labrie, V., Fukumura, R., Rastogi, A., Fick, L. J., Wang, W., Boutros, P. C., Kennedy, J. L., Semeralul, M. O., Lee, F. H., Baker, G. B., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp261 · Cited by 185
Ketamine and phencyclidine: the good, the bad and the unexpected
Lodge, D., & Mercier, M. S. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13222 · Cited by 184
Recent genetic findings in schizophrenia and their therapeutic relevance
Harrison, P. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114553647 · Cited by 183
Catts, V. S., Lai, Y. L., Weickert, C. S., Weickert, T. W., & Catts, S. V. (2015) · Biological Psychology · doi:10.1016/j.biopsycho.2015.10.013 · Cited by 183
Endogenous kynurenic acid disrupts prepulse inhibition
Erhardt, S., Schwieler, L., Emanuelsson, C., & Geyer, M. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.006 · Cited by 178
Lennox, B. R., Palmer-Cooper, E. C., Pollak, T., Hainsworth, J., Marks, J., Jacobson, L., Lang, B., Fox, H., Ferry, B., Scoriels, L., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30375-3 · Cited by 178
Lowther, C., Costain, G., Stavropoulos, D. J., Melvin, R., Silversides, C. K., Andrade, D. M., So, J., Faghfoury, H., Lionel, A. C., Marshall, C. R., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.83 · Cited by 174
Jones, R. S. G., & Bühl, E. H. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90341-h · Cited by 174
Steullet, P., Neijt, H. C., Cuénod, M., & Do, K. Q. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.10.014 · Cited by 173
Patz, S. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhg132 · Cited by 170
Tsutsui, K., Kanbayashi, T., Tanaka, K., Boku, S., Ito, W., Tokunaga, J., Mori, A., Hishikawa, Y., Shimizu, T., & Nishino, S. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-37 · Cited by 166
Translating the MAM model of psychosis to humans
Modinos, G., Allen, P., Grace, A. A., & McGuire, P. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.12.005 · Cited by 165 · cited 1×
“For example, systemic injection of methylazoxymethanol (MAM) to rats on gestational day 17 is known to produce schizophrenia-like phenotypes in adulthood (Modinos et al., 2015).”
BackgroundPitcher, G. M., Kalia, L. V., Ng, D., Goodfellow, N. M., Yee, K. T., Lambe, E. K., & Salter, M. W. (2011) · Nature Medicine · doi:10.1038/nm.2315 · Cited by 164
Jentsch, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00004-9 · Cited by 164
Alexander, K., Wu, H., Schwarcz, R. M., & Bruno, J. P. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2539-2 · Cited by 158
Löscher, W., & Hönack, D. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22942-1 · Cited by 158
Surface dynamics of GluN2B‐NMDA receptors controls plasticity of maturing glutamate synapses
Dupuis, J. P., Ladépêche, L., Seth, H., Bard, L., Varela, J. A., Mikasová, L., Bouchet, D., Rogemond, V., Honnorat, J., Hanse, E., et al. (2014) · The EMBO Journal · doi:10.1002/embj.201386356 · Cited by 155
Bodhinathan, K., Kumar, A., & Foster, T. C. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5485-09.2010 · Cited by 153 · cited 1×
“Modulation of intracellular redox state has also been shown to alter the NMDA responses at hippocampal synapses in the aged, but not young rats (Bodhinathan et al., 2010), which may be relevant for the study of age-dependent cognitive decline.”
BackgroundMiller, D. W., & Abercrombie, E. D. (1996) · Brain Research Bulletin · doi:10.1016/0361-9230(95)02144-2 · Cited by 146
Nyíri, G., Stephenson, F. A., Freund, T. F., & Somogyi, P. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00157-x · Cited by 144
Animal models of obstetric complications in relation to schizophrenia
Boksa, P. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.01.001 · Cited by 142
De novo mutations and rare variants occurring in NMDA receptors
XiangWei, W., Jiang, Y., & Yuan, H. (2017) · Current Opinion in Physiology · doi:10.1016/j.cophys.2017.12.013 · Cited by 140
Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system
Baxter, P. S., Bell, K. F. S., Hasel, P., Kaindl, A. M., Fricker, M., Thomson, D., Cregan, S. P., Gillingwater, T. H., & Hardingham, G. E. (2015) · Nature Communications · doi:10.1038/ncomms7761 · Cited by 139
Recent insights into the mode of action of memantine and ketamine
Johnson, J. W., Glasgow, N. G., & Povysheva, N. V. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.006 · Cited by 139
Bitanihirwe, B., Lim, M., Kelley, J., Kaneko, T., & Woo, T. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-71 · Cited by 137
Pearlman, D. M., & Najjar, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.05.001 · Cited by 132
Gray, L., van den Buuse, M., Scarr, E., Dean, B., & Hannan, A. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009085 · Cited by 130
d-Serine and Serine Racemase are Localized to Neurons in the Adult Mouse and Human Forebrain
Balu, D. T., Takagi, S., Puhl, M. D., Benneyworth, M. A., & Coyle, J. T. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0027-z · Cited by 130
Jiang, Z., Rompala, G. R., Zhang, S., Cowell, R. M., & Nakazawa, K. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.12.004 · Cited by 128
Self-citationArion, D., Huo, Z., Enwright, J. F., Corradi, J., Tseng, G. C., & Lewis, D. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.018 · Cited by 127
Karlsgodt, K. H., Robleto, K., Trantham‐Davidson, H., Jairl, C., Cannon, T. D., Lavín, A., & Jentsch, J. D. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.012 · Cited by 125
Zhang, Q., Tanaka, K., Sun, P., Nakata, M., Yamamoto, R., Sakimura, K., Matsui, M., & Kato, N. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.019 · Cited by 124
Kovacic, P., & Somanathan, R. (2009) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.1.10028 · Cited by 120
Losing your inhibition: Linking cortical GABAergic interneurons to schizophrenia
Inan, M., Petros, T. J., & Anderson, S. A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.013 · Cited by 119
Toxoplasmosis: A pathway to neuropsychiatric disorders
Tyebji, S., Seizova, S., Hannan, A. J., & Tonkin, C. J. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.11.012 · Cited by 117
Gallego, J. A., Blanco, E. A., Husain-Krautter, S., Fagen, E. M., Moreno-Merino, P., del Ojo-Jiménez, J. A., Ahmed, A. O., Rothstein, T. L., Lencz, T., & Malhotra, A. K. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.07.019 · Cited by 115
Kataoka, M., Matoba, N., Sawada, T., Kazuno, A.-A., Ishiwata, M., Fujii, K., Matsuo, K., Takata, A., & Kato, T. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.69 · Cited by 114
Hypoxia Enhances S-Nitrosylation-Mediated NMDA Receptor Inhibition via a Thiol Oxygen Sensor Motif
Takahashi, H., Shin, Y., Cho, S.-J., Zago, W. M., Nakamura, T., Gu, Z., Ma, Y., Furukawa, H., Liddington, R., Zhang, D., et al. (2007) · Neuron · doi:10.1016/j.neuron.2006.11.023 · Cited by 113
Sellgren, C. M., Kegel, M. E., Bergen, S. E., Ekman, C. J., Olsson, S., Larsson, M. K., Vawter, M. P., Backlund, L., Sullivan, P. F., Sklar, P. B., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.186 · Cited by 112
Suryavanshi, P. S., Ugale, R. R., Yilmazer‐Hanke, D., Stairs, D. J., & Dravid, S. M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12518 · Cited by 111
Immunological findings in psychotic syndromes: a tertiary care hospital's CSF sample of 180 patients
Endres, D., Perlov, E., Baumgärtner, A., Hottenrott, T., Dersch, R. S., Stich, O., & van Elst, L. T. (2015) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2015.00476 · Cited by 111
Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia
Nakazawa, K., Jeevakumar, V., & Nakao, K. (2017) · npj Schizophrenia · doi:10.1038/s41537-016-0003-3 · Cited by 110
Self-citationFernandes, C., Hoyle, E., Dempster, E. L., Schalkwyk, L. C., & Collier, D. A. (2005) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2005.00176.x · Cited by 108
Pan, H., Oliveira, B., Saher, G., Dere, E., Tapken, D., Mitjans, M., Seidel, J., Wesolowski, J., Wakhloo, D., Klein-Schmidt, C., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-017-0011-3 · Cited by 106
Engelhardt, J. V., Bocklisch, C., Tönges, L., Herb, A., Mishina, M., & Monyer, H. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00095 · Cited by 103 · cited 1×
“On the other hand, the GluN2D subunit of the NMDARs is expressed exclusively in GABAergic neurons but not pyramidal neurons in the cerebral cortex in adulthood (Alsaad et al., 2019; von Engelhardt et al., 2015).”
BackgroundErhardt, S., & Engberg, G. (2002) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.2002.00962.x · Cited by 103
Ladépêche, L., Planagumà, J., Thakur, S., Suárez, I., Hara, M., Borbely, J. S., Sandoval, A., Laparra-Cuervo, L., Dalmau, J. O., & Lakadamyali, M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.096 · Cited by 102
NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms
Snyder, M. A., & Gao, W. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.03.010 · Cited by 101
NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?
Masdeu, J. C., Dalmau, J. O., & Berman, K. F. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.02.006 · Cited by 99
Nucifora, L. G., Tanaka, T., Hayes, L. N., Kim, M., Lee, B. J., Matsuda, T., Nucifora, F. C., Sedlak, T. W., Mojtabai, R., Eaton, W. W., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.178 · Cited by 98
Patton, M. H., Bizup, B. T., & Grace, A. A. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2449-13.2013 · Cited by 94
Anti-NMDA receptor encephalitis and nonencephalitic HSV-1 infection
Salovin, A., Glanzman, J., Roslin, K., Armangué, T., Lynch, D. R., & Panzer, J. A. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000458 · Cited by 93
Hanson, E., Armbruster, M., Lau, L. A., Sommer, M., Klaft, Z., Swanger, S. A., Traynelis, S. F., Moss, S. J., Noubary, F., Chadchankar, J., et al. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.1392-18.2019 · Cited by 93
Neuregulin-1 and schizophrenia in the genome-wide association study era
Mostaid, M. S., Lloyd, D., Liberg, B., Sundram, S., Pereira, A. M., Pantelis, C., Karl, T., Weickert, C. S., Everall, I., & Bousman, C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.001 · Cited by 91
Hypoxia-induced modification of the receptor in the brain of the newborn piglet
Hoffman, D. J., McGowan, J. E., Marro, P. J., Mishra, O. P., & Delivoria‐Papadopoulos, M. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)91051-0 · Cited by 90
The Emergence of NMDA Receptor Metabotropic Function: Insights from Imaging
Doré, K., Aow, J., & Malinow, R. (2016) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2016.00020 · Cited by 90
Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment
Ellaithy, A., Younkin, J., González‐Maeso, J., & Logothetis, D. E. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.06.002 · Cited by 80
Brain state-dependent abnormal LFP activity in the auditory cortex of a schizophrenia mouse model
Nakao, K., & Nakazawa, K. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00168 · Cited by 72
Self-citationPicard, N., Takesian, A. E., Fagiolini, M., & Hensch, T. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0341-9 · Cited by 71 · cited 2×
“…(PV)-positive neuron-specific genetic ablation of GluN2A, which is highly expressed in GABA neurons, was also sufficient to ablate ketamine-induced changes in pyramidal cell activity in mouse visual cortex, suggesting that ketamine binds to GluN2A-containing PV neurons (Picard et al., 2019).”
BackgroundNMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys
Adams, B. W., Bradberry, C. W., & Moghaddam, B. (2001) · Synapse · doi:10.1002/syn.1114 · Cited by 70
Sapkota, K., Mao, Z., Synowicki, P., Lieber, D., Liu, M., Ikezu, T., Gautam, V., & Monaghan, D. T. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.230391 · Cited by 70
Self-citationBanerjee, A., Wang, H.-Y., Borgmann‐Winter, K. E., MacDonald, M. L., Kaprielian, H., Stucky, A., Kvasic, J., Egbujo, C. N., Ray, R., Talbot, K., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.115 · Cited by 67
Yu, Y., Lin, Y., Takasaki, Y., Wang, C., Kimura, H., Xing, J., Ishizuka, K., Toyama, M., Kushima, I., Mori, D., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0061-y · Cited by 66
Boddum, K., Hougaard, C. Ø., Lin, J. X.-Y., von Schoubye, N. L., Jensen, H. S., Grunnet, M., & Jespersen, T. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.02.024 · Cited by 65
Vullhorst, D., Mitchell, R. M., Keating, C. E., Roychowdhury, S., Karavanova, I. D., Tao-Cheng, J.-H., & Buonanno, A. (2015) · Nature Communications · doi:10.1038/ncomms8222 · Cited by 65
Lin, H., Hsu, F., Baumann, B. H., Coulter, D. A., Anderson, S. A., & Lynch, D. R. (2014) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.06.007 · Cited by 64
Urata, Y., Koga, K., Hirota, Y., Akiyama, I., Izumi, G., Takamura, M., Nagai, M., Harada, M., Hirata, T., Yoshino, O., et al. (2014) · American Journal of Reproductive Immunology · doi:10.1111/aji.12282 · Cited by 64
Donegan, J. J., Tyson, J. A., Branch, S. Y., Beckstead, M. J., Anderson, S. A., & Lodge, D. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.121 · Cited by 64
Tanaka, D. H., Toriumi, K., Kubo, K., Nabeshima, T., & Nakajima, K. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2786-11.2011 · Cited by 63
The Role of Serine Racemase in the Pathophysiology of Brain Disorders
Coyle, J. T., & Balu, D. T. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.10.002 · Cited by 63
Balla, A., Koneru, R., Smiley, J., Sershen, H., & Javitt, D. C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00230-5 · Cited by 62
Chittajallu, R., Wester, J. C., Craig, M. T., Barksdale, E., Yuan, X. Q., Akgül, G., Fang, C., Collins, D., Hunt, S., Pelkey, K. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00218-y · Cited by 62
Pocklington, A. J., O’Donovan, M. C., & Owen, M. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12489 · Cited by 61
Research Review: Cholinergic mechanisms, early brain development, and risk for schizophrenia
Ross, R. G., Stevens, K. E., Proctor, W. R., Leonard, S. S., Kisley, M. A., Hunter, S. K., Freedman, R., & Adams, C. E. (2009) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2009.02187.x · Cited by 60
The trapping block of NMDA receptor channels in acutely isolated rat hippocampal neurones
Sobolevsky, A. I., & Yelshansky, M. V. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.t01-2-00493.x · Cited by 60
Modification of modulatory sites of NMDA receptor in the fetal guinea pig brain during development
Mishra, O. P., & Delivoria‐Papadopoulos, M. (1992) · Neurochemical Research · doi:10.1007/bf00968404 · Cited by 57
Gulchina, Y., Xu, S., Snyder, M. A., Elefant, F., & Gao, W. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14101 · Cited by 56 · cited 1×
“It has been shown that MAM treatment decreases synaptic GluN2B protein levels and NMDA componentspontaneous EPSCs in mPFC Layer 5 pyramidal neurons at postnatal day (PND)-21 (Gulchina et al., 2017).”
BackgroundPathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia
Kannan, G., Gressitt, K. L., Yang, S. Y., Stallings, C. R., Katsafanas, E., Schweinfurth, L. A. B., Savage, C. L. G., Adamos, M. B., Sweeney, K., Origoni, A. E., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.162 · Cited by 56
Alsaad, H. A., DeKorver, N. W., Mao, Z., Dravid, S. M., Arikkath, J., & Monaghan, D. T. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2526-7 · Cited by 56
The Psychiatric Phenotype of Anti-NMDA Receptor Encephalitis
Gibson, L. L., Pollak, T. A., Blackman, G., Thornton, M., Moran, N. F., & David, A. S. (2018) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.17120343 · Cited by 55
NMDA Receptors in the Developing Brain and Effects of Noxious Insults
Waters, K. A., & Machaalani, R. (2004) · Neurosignals · doi:10.1159/000077523 · Cited by 51
NMDA receptor-dependent function and plasticity in inhibitory circuits
Moreau, A. W., & Kullmann, D. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.004 · Cited by 50
Würdemann, T. J., Kersten, M., Tokay, T., Guli, X., Kober, M., Rohde, M., Porath, K., Sellmann, T., Bien, C. G., Köhling, R., et al. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.027 · Cited by 49
D-Serine and Serine Racemase Are Associated with PSD-95 and Glutamatergic Synapse Stability
Lin, H., Jacobi, A. A., Anderson, S. A., & Lynch, D. R. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00034 · Cited by 49
All-optical synaptic electrophysiology probes mechanism of ketamine-induced disinhibition
Fan, L. Z., Nehme, R., Adam, Y., Jung, E. S., Wu, H., Eggan, K. C., Arnold, D. B., & Cohen, A. E. (2018) · Nature Methods · doi:10.1038/s41592-018-0142-8 · Cited by 49
α7-Nicotinic receptor expression and the anatomical organization of hippocampal interneurons
Adams, C. E., Stitzel, J. A., Collins, A. C., & Freedman, R. (2001) · Brain Research · doi:10.1016/s0006-8993(01)03115-8 · Cited by 48
Cardis, R., Cabungcal, J.-H., Dwir, D., Kim, Q., & Steullet, P. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.10.006 · Cited by 47
Inhibition of kynurenine aminotransferase II reduces activity of midbrain dopamine neurons
Linderholm, K. R., Tufvesson‐Alm, M., Larsson, M. K., Olsson, S. K., Goiny, M., Hajós, M., Erhardt, S., & Engberg, G. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.028 · Cited by 46
Schizophrenia-Like Dopamine Release Abnormalities in a Mouse Model of NMDA Receptor Hypofunction
Nakao, K., Jeevakumar, V., Jiang, S. Z., Fujita, Y., Diaz, N. B., Annan, C. A. P., Jaunarajs, K. L. E., Hashimoto, K., Belforte, J. E., & Nakazawa, K. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby003 · Cited by 45
Self-citationFlux-Independent NMDAR Signaling: Molecular Mediators, Cellular Functions, and Complexities
Balderas, P. M. D. O. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123800 · Cited by 45
Lin, C., & Lane, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00540 · Cited by 44
Grace, A. A. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.007 · Cited by 43
Chambers, A. R., Pilati, N., Balaram, P., Large, C. H., Kaczmarek, L. K., & Polley, D. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-17406-x · Cited by 41
Riebe, I., Seth, H., Culley, G., Dósa, Z., Radi, S., Strand, K., Fröjd, V., & Hanse, E. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13128 · Cited by 40 · cited 1×
“Thus, memantine appears to inhibit tonic (extrasynaptic) NMDARs in concentrations that do not affect synaptic NMDAR-mediated transmission (Riebe et al., 2016).”
BackgroundAnti-neuronal anti-bodies in patients with early psychosis
Mantere, O., Saarela, M., Kieseppä, T., Raij, T. T., Mäntylä, T. J. S., Lindgren, M., Rikandi, E., Stoecker, W., Teegen, B., & Suvisaari, J. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.027 · Cited by 40
Tufvesson‐Alm, M., Schwieler, L., Schwarcz, R. M., Goiny, M., Erhardt, S., & Engberg, G. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.003 · Cited by 40
Yamamoto, T., Nakayama, T., Yamaguchi, J., Matsuzawa, M., Mishina, M., Ikeda, K., & Yamamoto, H. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.10.049 · Cited by 39
Wang, H.-X., & Gao, W. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.11.024 · Cited by 39
Yenari, M. A., Bell-Stephens, T. E., Kotake, A. N., Powell, M. F., & Steinberg, G. K. (1998) · PubMed · Cited by 38
Lucchese, G. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00037 · Cited by 37
Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia
Tong, J., Huang, J., Luο, X., Chen, S., Cui, Y., An, H., Xiu, M., Tan, S., Wang, Z., Yuan, Y., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.017 · Cited by 37
Hagiwara, H., Iyo, M., & Hashimoto, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062438 · Cited by 36
Olaya, J. C., Heusner, C. L., Matsumoto, M., Sinclair, D., Kondo, M., Karl, T., & Weickert, C. S. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx122 · Cited by 36
Pathogenicity of Antibodies against NMDA Receptor: Molecular Insights into Autoimmune Psychosis
Jézéquel, J., Johansson, E. M., Leboyer, M., & Groc, L. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.05.002 · Cited by 36
Larimore, J. L., Zlatic, S. A., Gokhale, A., Tornieri, K., Singleton, K. S., Mullin, A. P., Tang, J. X., Talbot, K., & Faúndez, V. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.553750 · Cited by 35
Dukoff, D. J., Hogg, D. W., Hawrsyh, P. J., & Buck, L. T. (2014) · Journal of Experimental Biology · doi:10.1242/jeb.105825 · Cited by 35
Monoclonal antibodies from a patient with anti‐ NMDA receptor encephalitis
Sharma, R., Al‐Saleem, F. H., Panzer, J. A., Lee, J., Puligedda, R. D., Felicori, L. F., Kattala, C. D., Rattelle, A., Ippolito, G. C., Cox, R. H., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.592 · Cited by 35
Ju, P., & Cui, D. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv135 · Cited by 34
Frangeul, L., Kehayas, V., Sanchez-Mut, J. V., Fièvre, S., Krishna-K, K., Pouchelon, G., Telley, L., Bellone, C., Holtmaat, A. J. D. G., Gräff, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02172-1 · Cited by 34
Zhang, X.-Q., Feng, Z., & Chergui, K. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12758 · Cited by 33
Cited by
Flavonoids and their role in oxidative stress, inflammation, and human diseases
Jomova, K., Alomar, S. Y., Valko, R., Liska, J., Nepovimova, E., Kuca, K., & Valko, M. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111489 · Cited by 362
The schizophrenia risk gene C4 induces pathological synaptic loss by impairing AMPAR trafficking
Phadke, R. A., Brack, A., Fournier, L. A., Kruzich, E., Sha, M., Picard, I., Johnson, C., Stroumbakis, D., Salgado, M., Yeung, C., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-024-02701-7 · Cited by 20
Janz, P., Bainier, M., Marashli, S., Schoenenberger, P., Valencia, M., & Redondo, R. L. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02224-1 · Cited by 18
Metadata
- Authors
- Nakazawa, K., & Sapkota, K.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 205
- Pages
- 107426
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2980754671
- Cited by
- 275
- References
- 217
- FWCI
- 17.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.